A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.
Epistemonikos ID: 86a4e9b6dfe32667526b544698f61b41715bb1d6
First added on: May 09, 2024